Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer

Area of Science:

• Oncology
• Pharmacology
• Nanomedicine

Background:

• Taxane chemotherapy is limited in castration-resistant prostate cancer (CRPC) by resistance, toxicity, and non-response.
• Mechanisms of taxane resistance include the apoptotic pathway, ABC transporters, glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells.

Purpose of the Study:

• To review strategies for improving taxane-based chemotherapy in CRPC.
• To highlight approaches that overcome chemotherapy resistance, enhance drug delivery, and predict therapy response.

Main Methods:

• Literature review of strategies to overcome taxane resistance in CRPC.
• Discussion of targeted drug delivery systems (nanomedicine) and predictive biomarkers (circulating tumor cells).

Main Results:

• Identified key mechanisms mediating taxane resistance in CRPC.
• Outlined targeted nanomedicinal delivery strategies for improved efficacy.
• Discussed the use of circulating tumor cells for predicting docetaxel response.

Conclusions:

• Novel strategies involving bypassing resistance, targeted delivery, and response prediction show promise for clinical translation in CRPC.
• Further research and clinical validation are essential to enhance taxane efficacy and patient outcomes in CRPC.